Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group - Borchmann, Peter; Meißner, Julia (The lancet. Oncology, 2017)
Gesehen am 16.04.2018